![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » BMS Gets Priority Review for Investigational Leukemia Treatment
BMS Gets Priority Review for Investigational Leukemia Treatment
The FDA granted a priority review to Bristol-Myers Squibb’s CC-486 as a maintenance treatment for adults in remission with acute myeloid leukemia.
BMS based its new drug application on the results of a phase 3 trial that showed an improvement in overall survival for patients receiving maintenance treatment with CC-486 vs. a placebo.
CC-486 is not currently approved for use in any country. The& FDA& is expected to make a decision on approval by Sept. 3.
Upcoming Events
-
21Oct